Active Filter(s):
Details:
The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.
Lead Product(s): Artemether,Lumefantrine,Amodiaquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: GHIT Fund
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Financing December 13, 2023